The premier life science incubator empowering and enabling innovators to deliver life-enhancing health and wellness solutions to people around the globe.
JLABS in innovation hotspots around the world
Because we know great ideas can come from everywhere. Whenever you feel inspired and are ready to move your breakthrough ideas in healthcare forward to reach patients and consumers, we have a community of state of the art JLABS waiting for you.
"South San Francisco, Calif.-based Boost Biomes’ technology works to increase the productivity of beneficial microbes that impact how plants use water and soil nutrients."
Wall Street Journal
If you’re driven by something that’s very mission-based, very values-based, then you’re willing to buck the system.
Entrepreneur Magazine
“Every week I meet companies on the edge of innovation and health care—new consumer products, pharmaceutical or biotech developments, as well as medical devices. I really do feel like I have the coolest job in San Diego.”
San Diego Magazine
"With the continued acceleration of novel science and health care technologies in areas like artificial intelligence, digital therapeutics and the human microbiome we have tremendous opportunity to search the haystack in new and exciting ways."
Scientific American
"Xconomy: What do you wish your 25-year-old self knew (or was told?)
Melinda Richter: "You are good enough. You’re strong enough. You’re capable enough."
Xconomy
"Bringing the NY entrepreneurs and startups together with the investors is what we're all about."
Life Science Leader
"Silicon Valley isn't the only place to be a successful entrepreneur - you can be a hero in your home town - and that innovation resides as much outside big companies like J&J as it does inside; JLabs looks to catalyse innovation and accelerate it."
The Straits Times
Residents
Check out what some of our resident companies are working on, how they're tackling challenging problems in new and innovative ways.
Riding the Start-Up Roller Coaster: What It's Really Like to Be a Healthcare Entrepreneur
Biotech Lab Space in San Francisco, CA | JLABS
By: Ideaya Biosciences
IDEAYA Biosciences raised a $94M crossover Series B financing to develop next generation biomarker-enabled synthetic lethality therapies.
Coworking Lab Space in San Diego, CA | JLABS
By: Sirenas
Sirenas LLC. annouced today they have entered a muti-target research collaboration agreement with Bristol-Myers Squibb to deploy a drug discovery platform against undisclosed challenging therapeutic t...
Coworking Lab Space in Toronto, ON | JLABS
By: Nanovista Inc.
Nanovista Inc. closes $2.3 million seed round to advance its multimodal visualization agent towards clinical trials
JLABS @ MBC BioLabs - Locations | JLABS
By: Symic Biomedical
Symic Bio Completes the MODIFY2 Phase 2 Trial of SB-061 for the Treatment of Knee Osteoarthritis
Biotech Lab Space in San Francisco, CA | JLABS
By: Imago Biosciences
Imago BioSciences Receives FDA Approval of IND Application for the Treatment of Myeloid Malignancies
Coworking Lab Space in Toronto, ON | JLABS
By: Advanced Proteome Therapeutics
Advanced Proteome Therapeutics Corporation (APC), a therapeutics discovery and development company, and ImmunoBiochem Corporation, announced they are entering into a Collaboration and Option agreement...
Wet Lab & Office Space in Houston, TX | JLABS
By: ImmunoMet Therapeutics
JLABS TMC Company finds Growth in Shrinking Cells
Coworking Lab Space in Toronto, ON | JLABS
By: AVROBIO Inc.
With a potential cure for lysosomal storage disorders in hand, Avrobio raises $60M to back gene therapy pipeline
Coworking Lab Space in Toronto, ON | JLABS
By: AVROBIO Inc.
Avrobio, announced they have completed a $60M Series B round to back their gene therapy pipeline
Coworking Lab Space in Toronto, ON | JLABS
By: Biotagenics Inc.
Biotagenics Partners with University of Ottawa and CHEO on a $9.1 Million Project with Genome Canada to Develop Therapies for Inflammatory Bowel Disease
Coworking Lab Space in San Diego, CA | JLABS
By: Ensysce
Ensysce Biosciences has received Fast Track designation from the FDA for the development of abuse-resistant opioid drug PF614
